Published in J Biol Inorg Chem on April 06, 2010
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. Inorg Chem (2011) 0.89
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics (2010) 0.89
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics (2013) 0.86
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. J Inorg Biochem (2012) 0.86
Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells. Inorg Chem (2011) 0.85
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Inorg Chem (2013) 0.85
Ruthenium(II) arene complexes with chelating chloroquine analogue ligands: synthesis, characterization and in vitro antimalarial activity. Dalton Trans (2012) 0.84
Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity. Inorganica Chim Acta (2012) 0.79
DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets. J Biol Inorg Chem (2011) 0.79
Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution. Inorg Chem (2013) 0.76
A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(II) complex as potential hR2 RNR inhibitors. Chem Commun (Camb) (2013) 0.75
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Cdk2 knockout mice are viable. Curr Biol (2003) 3.92
Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem (2001) 1.61
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem (1999) 1.47
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res (1999) 1.41
Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol (2001) 1.33
Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J Am Chem Soc (2002) 1.26
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer (2001) 1.24
Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores. Phytochemistry (1997) 1.21
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Chemistry (2003) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today (2008) 1.06
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. J Am Chem Soc (2006) 1.01
Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action. Biochemistry (1999) 0.93
The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. Inorg Chem (2007) 0.93
From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors. J Org Chem (2009) 0.92
Involvement of c-Jun N-terminal kinase in G2/M arrest and FasL-mediated apoptosis induced by a novel indoloquinoline derivative, IQDMA, in K562 cells. Leuk Res (2007) 0.88
Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull (Tokyo) (1983) 0.86
Synthesis and cytotoxic activity evaluation of indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline derivatives. Bioorg Med Chem (2002) 0.85
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. J Med Chem (2006) 0.84
Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells. Chem Biol Interact (2008) 0.84
A novel indoloquinoline derivative, IQDMA, induces S-phase arrest and apoptosis in promyelocytic leukemia HL-60 cells. Cell Biol Toxicol (2006) 0.83
Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives. J Med Chem (1992) 0.83
Syntheses and beta-adrenergic blocking activities of carbostyril derivatives. Chem Pharm Bull (Tokyo) (1981) 0.82
Evaluation of partial beta-adrenoceptor agonist activity. Br J Clin Pharmacol (1997) 0.81
Expeditious synthesis and cytotoxic activity of new cyanoindolo[3,2-c]quinolines and benzimidazo[1,2-c]quinazolines. Bioorg Med Chem Lett (2000) 0.80
Synthesis and cytotoxic evaluation of a series of gamma-substituted gamma-aryloxymethyl-alpha-methylene-gamma-butyrolactones against cancer cells. Pharm Res (2000) 0.78
2(1H)-quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives. J Med Chem (1988) 0.78
2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. J Med Chem (1989) 0.78
Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds. Chem Pharm Bull (Tokyo) (1983) 0.77
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. J Thorac Oncol (2015) 2.17
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res (2003) 1.83
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet (2011) 1.65
Antitumour metal compounds: more than theme and variations. Dalton Trans (2007) 1.64
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev (2006) 1.55
Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res (2007) 1.52
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J Med Chem (2009) 1.51
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat (2007) 1.35
Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB J (2005) 1.35
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem (2009) 1.32
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem (2003) 1.25
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun (2009) 1.25
Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat (2008) 1.24
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther (2008) 1.23
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem (2007) 1.19
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. J Cell Sci (2006) 1.12
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
The activin axis in liver biology and disease. Mutat Res (2006) 1.10
Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10
Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol (2002) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol (2009) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem (2007) 1.08
Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem (2009) 1.08
Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia (2005) 1.08
Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (2009) 1.07
Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol (2013) 1.07
FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis (2007) 1.06
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat (2010) 1.05
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J Inorg Biochem (2010) 1.04
Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology (2011) 1.04
Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem (2011) 1.04
Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res (2012) 1.03
Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem (2007) 1.03
Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem Pharmacol (2007) 1.03
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther (2011) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J Inorg Biochem (2007) 1.01
Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans (2009) 1.00
Gallium in cancer treatment. Curr Top Med Chem (2004) 0.98
Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem (2011) 0.98
Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol (2006) 0.98
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem (2005) 0.97
Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. J Inorg Biochem (2002) 0.97
Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. Eur J Med Chem (2011) 0.96